dc.contributor.author | Hacıoğlu, Muhammet Bekir | |
dc.contributor.author | Köstek, Osman | |
dc.contributor.author | Kurt, Nazmi | |
dc.contributor.author | Küçükarda, Ahmet | |
dc.contributor.author | Gökyer, Ali | |
dc.contributor.author | Ustabaşıoğlu, Fethi Emre | |
dc.contributor.author | Karataş, Fatih | |
dc.contributor.author | Tunçbilek, Nermin | |
dc.contributor.author | Uzunoǧlu, Sernaz | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Çiçin, İrfan | |
dc.contributor.author | Erdoğan, Bülent | |
dc.date.accessioned | 2019-12-27T17:21:14Z | |
dc.date.available | 2019-12-27T17:21:14Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Hacıoğlu, M. B., Köstek, O., Kurt, N., Küçükarda, A., Gökyer, A., Ustabaşıoğlu, F. E. ... Erdoğan, B. (2019). Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102. Journal of B.U.ON., 24(5), 2198-2204. | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4786 | |
dc.description.abstract | Purpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). Methods: A total of 36 mCRC patients, who received regorafenib or TAS-102 in the third-line and subsequent settings were assessed in the analysis. SMM changes were assessed with CT scans findings, and they were categorized into two groups as SMM-loss (SMM decrease ≥2%) and SMM-stable (SMM change <2%). Results: The SMM change after regorafenib therapy was significantly worse compared with TAS-102 therapy (p=0.001). The median overall survival (OS) was longer in SMM-stable group than in SMM-loss group (12.8 months; 95%CI:9.8-15.7) vs. 6.4 months; 95%CI:5.2-7.7, respectively;p=0.04). Cox regression analysis showed that SMM loss was independent prognostic indicator for OS (HR, 2.87; 95%CI: 1.07-7.42, p=0.03). Conclusion: Although patients who received regorafenib had more SMM loss than those who received TAS-102, there was no difference in OS between drugs. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Zerbinis Publications | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Metastatic Colorectal Cancer | en_US |
dc.subject | Regorafenib | en_US |
dc.subject | TAS- 102 | en_US |
dc.subject | Sarcopenia | en_US |
dc.subject | Skeletal Muscle Mass | en_US |
dc.title | Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102 | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of B.U.ON. | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9717-4581 | en_US |
dc.identifier.volume | 24 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 2198 | en_US |
dc.identifier.endpage | 2204 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q3 | en_US |